Press Releases

Date Headline
12/5/2022
Zymeworks to Transfer Stock Listing to Nasdaq
 Summary
VANCOUVER, British Columbia --(BUSINESS WIRE)--Dec. 5, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced today that it has elected to transfer its stock exchange listing from the New York Stock Exchange (NYSE) to The  Continue Reading
11/29/2022
Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals
 Summary
VANCOUVER, British Columbia --(BUSINESS WIRE)--Nov. 29, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976, as  Continue Reading
11/22/2022
Zymeworks Announces Participation in Upcoming Investor Conference
 Summary
VANCOUVER, British Columbia --(BUSINESS WIRE)--Nov. 22, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference: 5 th Annual  Continue Reading
11/21/2022
Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Hormone-Receptor Positive (HR+) Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)
 Summary
VANCOUVER, British Columbia --(BUSINESS WIRE)--Nov. 21, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the publication of an abstract highlighting new clinical data for zanidatamab, a HER2-targeted  Continue Reading
11/8/2022
Zymeworks Provides Corporate Update and Reports Third Quarter 2022 Financial Results
 Summary
Announced exclusive license agreement with Jazz Pharmaceuticals to develop and commercialize zanidatamab, Zymeworks’ lead clinical candidate, for total potential payments of up to $1.76 billion , plus royalties on net sales Hosted Early Research and Development day highlighting progress in  Continue Reading
10/20/2022
Zymeworks Early R&D Day Highlights Progress in Development of Novel Pipeline Assets and Applications of Proprietary Next-Generation Technology Platforms
 Summary
Program beginning today at 8:30 AM Eastern Standard Time (EST) to feature updates and perspectives from Zymeworks senior leadership and scientific experts Progress in early-stage research designed to support Company goal to file up to five new Investigational New Drug (IND) applications in the next  Continue Reading
10/19/2022
Zymeworks To Host Conference Call on Exclusive Licensing Agreement of Zanidatamab
 Summary
Jazz Pharmaceuticals to obtain exclusive development and commercialization rights in key markets including the U.S. , Europe and Japan Zymeworks to receive $50 million upfront payment, a second payment of $325 million , at Jazz’s option, and further potential regulatory and commercial milestones  Continue Reading
10/19/2022
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
 Summary
Jazz to obtain exclusive development and commercialization rights in  key markets  including the U.S.,  Europe  and  Japan   Zymeworks to receive  $50 million  upfront payment, a second payment of  $325 million , at Jazz's option, and further potential regulatory and commercial milestones for total  Continue Reading
10/18/2022
Zymeworks to Host Third Quarter Results Conference Call
 Summary
VANCOUVER, British Columbia --(BUSINESS WIRE)--Oct. 18, 2022-- Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its third quarter 2022 financial results after market close on November 8 th  Continue Reading
10/13/2022
Zymeworks Completes Plan to Become Delaware Corporation
 Summary
VANCOUVER, British Columbia --(BUSINESS WIRE)--Oct. 13, 2022-- Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the completion of its previously announced intention to complete a series  Continue Reading
Displaying 1 - 10 of 47
Copyright 2022 , Zymeworks Inc.